Placeholder Banner

Heading East: Biopharma International Expansion to China and Asia

December 17, 2018

China’s rapidly growing economy has helped drive unprecedented growth in its healthcare market. Driven by pro-innovation and pro-biotechnology policy trends, China is becoming a prime market for biopharmaceutical companies globally; nearly 90% of the firms in L.E.K.’s biopharma survey expressed interest in a China expansion. Furthermore, Asia, not only contains 60 percent of the world’s population, it also accounts for 30% of the world’s GDP and pharmaceutical spending.  
While recent policy reforms in China are expected to create enormous opportunities for global firms, China nevertheless remains a complicated market for emerging biotech companies and multinational corporations alike. 

Download Full Comments Below
Biopharma International Expansion To China And Asia For Web
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…